[Long-term low molecular weight heparin protection during pregnancy for the recurrent fetal loss].
Recurrent fetal loss affects 1 to 5% women of the fertile age all over the world. Pathogenesis of recurrent early or late fetal loss remains unclear and therefore the LMHW administration during pregnancy has not been sorted out so far. Our trial deals with a cohort of 51 pregnant women with recurrent fetal loss in their personal history treated by long-term administration of LMWHs which was compared with a cohort of healthy women LMWHs untreated. 91% effectiveness of a long-term LMWH protection means in fact 43 liveborn babies delivered without any complications during pregnancy and delivery to 47 women - 30 of these women were primiparas.
Hajsmanová
Z
Z
Hematologický úsek, UKBH FN a LF UK, Plzen. hajsmanova@fnplzen.cz
Slechtová
J
J
Sigutová
P
P
Ulcová-Gallová
Z
Z
D000026:Abortion, Habitual / Q000209:etiology / Q000517:prevention & control*; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D019851:Thrombophilia / Q000150:complications / Q000188:drug therapy
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight